Prothea Technologies at ECBIP 2025

5/7/2025, Published by Prothea Technologies Ltd.

Edinburgh, UK, May 7, 2025 - Prothea Technologies, https://prothea.tech, the private medical technology company with a vision to offer lung cancer biopsy and treatment in a single hospital visit, is pleased to announce that its technology will feature at the 8th European Congress for Bronchology and Interventional Pulmonology (ECBIP, Lisbon: May 8-10).

In a session on Lung Nodules, Dr Adam Marshall, Consultant Interventional Pulmonologist at Royal Infirmary of Edinburgh, will present a paper entitled “Molecular Visualisation and Direct Instrumentation of Peripheral Lung Nodules with a Miniaturised Flexible Microendoscope”. The session will be chaired by Dr Michael Doris, Director, Pulmonary Medicine Department, Mitera General Hospital, Athens, Greece, and Professor Dr Daniela Gompelmann, Professor of Interventional Pulmonology and senior consultant in the Department of Pulmonology at the Medical University of Vienna, Austria.

Dr Marshall is the principal investigator for the Precision Lung clinical trial that, subject to the relevant clearances, is expected to start later in 2025. The trial will record the safety, procedural success and diagnostic yield of the Prothea imaging and biopsy technology in a series of patients with suspicious lung nodules. It is co-sponsored by the University of Edinburgh and NHS Lothian.

The Prothea Imaging and Biopsy system is not currently cleared for use in any country.

Notes for Editors

Lung cancer is the third most common form of cancer in the U.S. and annually claims more lives than breast, prostate and colon cancer combined. Screening programmes facilitate the early detection of suspicious lesions, but delivering value from these initiatives requires a significant increase in biopsy performance, presenting a challenge for hospitals already grappling with low biopsy yields and false negatives.

Prothea has developed a Microendoscope that combines with an Image Processing System to characterise small lesions, in situ, at a molecular level, for greater biopsy accuracy. A laser ablation catheter is in development for the treatment of lesions immediately following biopsy. The integration of these two systems (real-time imaging and ablation) is designed to streamline biopsy and treatment into a single hospital visit, reducing time-to-treat from weeks to minutes, thereby relieving hospital pressures and improving patient outcomes.

The Company’s clinical pipeline includes an advanced program supported by Wellcome, that will evaluate Prothea’s technologies in patients with lung infections in intensive care units, enabling earlier selection of optimal drug therapy.

Prothea’s Image Processing Systems measure the differential in time, between healthy and abnormal tissue, for the round trip of light from and to a laser source. Proprietary software will be developed, enhanced by artificial intelligence, to evaluate large volume data sets – developing in-procedure information to support clinical decisions. Micro-engineered catheters and molecular imaging also offer a well-controlled system for hyper-local drug delivery.

Prothea Technologies is a spinout from the universities of Edinburgh and Bath and in April 2024 completed a €12m Series A financing provided by Earlybird Venture Capital, Mérieux Equity Partners and NRW.BANK.

For further information, please contact:
Dr. Anne Moore, COO
Email: anne.moore@prothea.tech

Prothea Technologies Limited City Point, 3rd Floor, 65 Haymarket Terrace, Edinburgh, Scotland, EH12 5HD

Registered company number SC701542